Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) General Counsel Sells $283,511.28 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 4,084 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $69.42, for a total transaction of $283,511.28. Following the completion of the sale, the general counsel owned 72,315 shares of the company’s stock, valued at $5,020,107.30. This trade represents a 5.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Bryan Wahl also recently made the following trade(s):

• On Thursday, March 19th, Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $67.00, for a total value of $283,477.00.
• On Wednesday, March 18th, Bryan Wahl sold 4,125 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $68.71, for a total value of $283,428.75.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS opened at $64.51 on Friday. Tarsus Pharmaceuticals, Inc. has a 12-month low of $38.51 and a 12-month high of $85.25. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -39.82 and a beta of 0.55. The stock’s 50 day moving average price is $69.12 and its two-hundred day moving average price is $70.30. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. On average, analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Deep Track Capital LP grew its stake in Tarsus Pharmaceuticals by 71.4% during the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after buying an additional 1,250,000 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Tarsus Pharmaceuticals by 34.1% in the 4th quarter. Janus Henderson Group PLC now owns 1,930,325 shares of the company’s stock valued at $158,062,000 after buying an additional 491,326 shares during the period. Norges Bank acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at approximately $19,095,000. M&T Bank Corp raised its position in shares of Tarsus Pharmaceuticals by 11,730.0% in the 4th quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock valued at $35,791,000 after buying an additional 433,424 shares in the last quarter. Finally, MPM Bioimpact LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth approximately $13,834,000. Institutional investors own 90.01% of the company’s stock.

Key Stories Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

Analyst Ratings Changes

TARS has been the topic of several research reports. Guggenheim upped their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, March 16th. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Finally, Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $91.83.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.